Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | GBA1 | P04062 | 6/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19224588 | 1.00 | CYP19A1 (0.56) | CYP19A1HRH4HRH3GBA1EPHX2 | |
| SCHEMBL18757279 | 1.00 | CYP19A1 (0.56) | CYP19A1HRH4HRH3GBA1EPHX2 | |
| SCHEMBL10299507 | 0.98 | HRH4 (0.54) | CYP19A1HRH4HRH3GBA1EPHX2 | |
| SCHEMBL10312474 | 0.94 | HRH4 (0.49) | CYP19A1HRH4HRH3GBA1EPHX2 | |
| SCHEMBL10079149 | 0.93 | HRH4 (0.57) | CYP19A1HRH4HRH3GBA1EPHX2 | |
| SCHEMBL18489327 | 0.93 | HRH4 (0.57) | CYP19A1HRH4HRH3GBA1EPHX2 | |
| SCHEMBL18489275 | 0.91 | HRH4 (0.56) | CYP19A1HRH4HRH3GBA1EPHX2 | |
| SCHEMBL19479091 | 0.91 | HRH4 (0.56) | CYP19A1HRH4HRH3GBA1EPHX2 | |
| SCHEMBL22762136 | 0.91 | HRH4 (0.56) | CYP19A1HRH4HRH3GBA1EPHX2 | |
| SCHEMBL18494157 | 0.91 | HRH4 (0.56) | CYP19A1HRH4HRH3GBA1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399405-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120172311-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120101047-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapetics Inc. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101047-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | CYP19A1 1614/4885HRH4 1851/4885HRH3 2016/4885 |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | CYP19A1 2899/4885HRH4 4460/4885HRH3 3972/4885 |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | PCNA, MKI67, NFATC1 | CYP19A1 2887/4885HRH4 3022/4885HRH3 2281/4885 |
| US-20120172311-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | CYP19A1 3811/4885HRH4 4334/4885HRH3 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.